Literature DB >> 34231519

Astrocyte activation imaging with 11C-acetate and amyloid PET in mild cognitive impairment due to Alzheimer pathology.

Michael Tran Duong1,2,3, Yin Jie Chen1, Robert K Doot1, Anthony J Young1, Hsiaoju Lee1, Jenny Cai1, Arun Pilania2, David A Wolk2,3, Ilya M Nasrallah1,3.   

Abstract

BACKGROUND: Neuroinflammation is a well-known feature of early Alzheimer disease (AD) yet astrocyte activation has not been extensively evaluated with in vivo imaging in mild cognitive impairment (MCI) due to amyloid plaque pathology. Unlike neurons, astrocytes metabolize acetate, which has potential as a glial biomarker in neurodegeneration in response to AD pathologic features. Since the medial temporal lobe (MTL) is a hotspot for AD neurodegeneration and inflammation, we assessed astrocyte activity in the MTL and compared it to amyloid and cognition.
METHODS: We evaluate spatial patterns of in vivo astrocyte activation and their relationships to amyloid deposition and cognition in a cross-sectional pilot study of six participants with MCI and five cognitively normal participants. We measure 11C-acetate and 18F-florbetaben amyloid standardized uptake values ratios (SUVRs) and kinetic flux compared to the cerebellum on PET, with MRI and neurocognitive testing.
RESULTS: MTL 11C-acetate SUVR was significantly elevated in MCI compared to cognitively normal participants (P = 0.03; Cohen d = 1.76). Moreover, MTL 11C-acetate SUVR displayed significant associations with global and regional amyloid burden in MCI. Greater MTL 11C-acetate retention was significantly related with worse neurocognitive measures including the Montreal Cognitive Assessment (P = 0.001), word list recall memory (P = 0.03), Boston naming test (P = 0.04) and trails B test (P = 0.04).
CONCLUSIONS: While further validation is required, this exploratory pilot study suggests a potential role for 11C-acetate PET as a neuroinflammatory biomarker in MCI and early AD to provide clinical and translational insights into astrocyte activation as a pathological response to amyloid.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34231519      PMCID: PMC8800345          DOI: 10.1097/MNM.0000000000001460

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  44 in total

1.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

2.  Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study.

Authors:  Peter S Bloomfield; Sudhakar Selvaraj; Vincenzo de Paola; Oliver D Howes; Mattia Veronese; Gaia Rizzo; Alessandra Bertoldo; David R Owen; Michael Ap Bloomfield; Ilaria Bonoldi; Nicola Kalk; Federico Turkheimer; Philip McGuire
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

Review 3.  Labeled acetate as a marker of astrocytic metabolism.

Authors:  Matthias T Wyss; Pierre J Magistretti; Alfred Buck; Bruno Weber
Journal:  J Cereb Blood Flow Metab       Date:  2011-06-08       Impact factor: 6.200

4.  Bilateral symmetry of morphologic lesions in Alzheimer's disease.

Authors:  J Moossy; G S Zubenko; A J Martinez; G R Rao
Journal:  Arch Neurol       Date:  1988-03

5.  Acetate reduces microglia inflammatory signaling in vitro.

Authors:  Mahmoud L Soliman; Kendra L Puig; Colin K Combs; Thad A Rosenberger
Journal:  J Neurochem       Date:  2012-09-28       Impact factor: 5.372

6.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

7.  Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis.

Authors:  Joanne M Wells; David A Mankoff; Mark Muzi; Finbarr O'Sullivan; Janet F Eary; Alexander M Spence; Kenneth A Krohn
Journal:  Mol Imaging       Date:  2002-07       Impact factor: 4.488

8.  Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach.

Authors:  Vijay Dhawan; Yilong Ma; Vandhana Pillai; Phoebe Spetsieris; Thomas Chaly; Abdelfatihe Belakhlef; Claude Margouleff; David Eidelberg
Journal:  J Nucl Med       Date:  2002-10       Impact factor: 10.057

9.  Acute alcohol intoxication decreases glucose metabolism but increases acetate uptake in the human brain.

Authors:  Nora D Volkow; Sung Won Kim; Gene-Jack Wang; David Alexoff; Jean Logan; Lisa Muench; Colleen Shea; Frank Telang; Joanna S Fowler; Christopher Wong; Helene Benveniste; Dardo Tomasi
Journal:  Neuroimage       Date:  2012-08-28       Impact factor: 6.556

10.  Apolipoprotein E4 Alters Astrocyte Fatty Acid Metabolism and Lipid Droplet Formation.

Authors:  Brandon C Farmer; Jude Kluemper; Lance A Johnson
Journal:  Cells       Date:  2019-02-20       Impact factor: 6.600

View more
  1 in total

Review 1.  PET Imaging of Neuroinflammation in Alzheimer's Disease.

Authors:  Rong Zhou; Bin Ji; Yanyan Kong; Limei Qin; Wuwei Ren; Yihui Guan; Ruiqing Ni
Journal:  Front Immunol       Date:  2021-09-16       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.